| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Quest Diagnostics Inc.$233.01
-1.29 (-0.55%)
C 51Pipeline Score Diagnostics · Commercial
Market Cap
21.04 B
EPS
8.86
P/E Ratio
21.86 $
Value Trade
125.70 M
SEC Financials
Q2 2026Dilution Risk
Revenue
3.04 B
Total Assets
16.94 B
Total Liabilities
16.94 B
Equity
7.52 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
626.00 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Jul 23, 2026
Overview
Volume
872.68 K
52 Week Range
160.02 - 213.50
% held by Insiders
0.49 %
% held by Institutions
96.05 %
Enterprise Value
27.12 B
Total Shares
110.70 M
Short %
3.18 %
Float Shares
110.36 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Quest Diagnostics Inc.
87Total events
1Upcoming
11Tier-1 (high impact)
2016 – 2027Coverage
Upcoming catalysts 1
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
●PublicationPresentation
Subscribe to view catalyst details
TBD
▲Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C51
Pipeline Score $3.1B
Pipeline ValueValuation Signal
3
Drugs Scored0.5x
rNPV / MCap Top 80%
Mid Cap (rank 184 of 913)
Percentile RankQuest Diagnostics Inc. carries a moderate pipeline score (51/100), with $3.6B risk-adjusted pipeline value, led by HDT 321 in Vaccine (Phase 1), across $64B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDT 321 Monoclonal antibody | Vaccine | Phase 1 | NCT06799013 | 43% | $3.2B | RECRUITING | 48 | STALLED | C (44) | Jul 1, 2027 | - | May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DGX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DGX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-DGX
Jul 30, 2026▼ -0.5%today
Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
A recent study by Quest Diagnostics found that women with bacterial vaginosis (BV) are over three times more likely to be co-infected with sexually transmitted infections (STIs) compared to those without BV. Analyzing data from over 1.5 million women, the study revealed that 12% of BV-positive women had at least one STI. The findings emphasize the need for STI testing in women diagnosed with BV to prevent serious health complications.
Read more →-DGX
Jul 23, 2026▲ +8.6%on this news
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
Quest Diagnostics reported strong financial results for the second quarter of 2026, with revenues reaching $3.04 billion, a 10.2% increase from the previous year. The company also raised its full-year guidance for revenues and earnings per share, reflecting robust growth across its service channels. Notable advancements include collaborations in kidney care and significant revenue growth in Advanced Diagnostics.
Read more →-DGX
Jul 8, 2026Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
Quest Diagnostics has announced the integration of its Haystack MRD test and Comprehensive Genomic Profiling services into OncoEMR, enhancing access for clinicians. This pilot program, in collaboration with the American Oncology Network, aims to streamline test ordering and reporting for cancer care providers. The full integration is set to launch nationwide later this year.
Read more →-DGX
Jun 29, 2026Quest Diagnostics Foundation Commits Nearly $5 Million to Improving Health Outcomes and Food Security in Miami-Dade County, Florida
The Quest Diagnostics Foundation has announced a nearly $5 million grant to four local organizations in Miami-Dade County to improve health outcomes and food security. The initiative aims to reach 15,000 residents over two years, providing no-cost laboratory testing and support services. Collaborating organizations will focus on chronic diseases and maternal health, enhancing access to healthcare in vulnerable communities.
Read more →-DGX
Jun 25, 2026Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs
Attunio Health has expanded its AI-powered precision psychiatry platform by partnering with Quest Diagnostics and Getlabs. This collaboration allows for advanced diagnostic testing and at-home blood collection, enhancing accessibility to mental healthcare. The initiative aims to provide continuous, data-driven psychiatric care, moving beyond traditional methods reliant on episodic visits.
Read more →-DGX
Jun 24, 2026Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
Quest Diagnostics has received approval from the New York State Department of Health for its Haystack MRD test, which detects minimal residual disease in patients with solid tumors. This approval allows the test to be used in all 50 states, enhancing access for patients and providers. The test's effectiveness has been validated in clinical studies, demonstrating its potential to improve patient management.
Read more →-DGX
Jun 18, 2026UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
A new study published in Nature Communications reveals that nearly 70% of Klebsiella pneumoniae strains, responsible for UTIs and other infections, are resistant to commonly used antibiotics. Conducted by Hackensack Meridian CDI and Quest Diagnostics, the research indicates a troubling shift as these bacteria spread beyond hospitals into communities. The findings underscore the urgent need for new treatment options and ongoing surveillance.
Read more →-DGX
Jun 17, 2026Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics has announced that it will release its second quarter financial results for 2026 on July 23, 2026, before the market opens. A conference call to discuss these results will take place at 8:30 a.m. Eastern Time on the same day. Participants can access the call via specific phone numbers and will have the option to listen to a replay afterward.
Read more →-DGX
Jun 16, 2026Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics has released its 2025 Corporate Responsibility Report, highlighting its achievements in healthcare access, employee engagement, governance, and environmental sustainability. The report showcases significant contributions, including over one million discounted testing requisitions and improved employee retention. Additionally, the company has enhanced its governance structures and achieved ISO certification for environmental management.
Read more →-DGX
May 19, 2026Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics has announced a quarterly cash dividend of $0.86 per share, which will be paid on July 22, 2026, to shareholders of record on July 8, 2026. This decision reflects the company's ongoing commitment to returning value to its shareholders. Quest Diagnostics continues to play a crucial role in healthcare by providing diagnostic insights.
Read more →-DGX
Apr 28, 2026Quest Diagnostics Prices $500 Million of Senior Notes
Quest Diagnostics has announced the pricing of $500 million in senior notes due 2036. The company plans to use the proceeds for general corporate purposes, including repaying existing debt. The offering is expected to close on May 6, 2026, pending customary conditions. The announcement highlights Quest's ongoing commitment to healthcare diagnostics.
Read more →-DGX
Apr 21, 2026Quest Diagnostics Reports First Quarter 2026 Financial Results Raises Revenue and EPS Guidance for Full Year 2026 First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth First quarter
Quest Diagnostics reported its first quarter 2026 financial results, highlighting a revenue increase of 9.2% year-over-year to $2.90 billion. The diluted earnings per share rose by 15.5%, prompting the company to raise its full-year guidance for both revenue and EPS. Strategic initiatives, including diagnostics advancements and AI tool launches, contributed to this growth. The company emphasized its commitment to innovative solutions and operational excellence as key drivers of its performance.
Read more →-DGX
Apr 17, 2026City of Hope to Evaluate Quest Diagnostics’ Haystack MRD® for Guiding Patient Management in Multiple Cancers
Quest Diagnostics has partnered with City of Hope to evaluate the Haystack MRD ctDNA test in managing patients with solid tumors, including breast, colorectal, ovarian, and prostate cancers. The multi-year study will involve around 500 patients and aims to improve early detection and treatment monitoring. The collaboration seeks to leverage advanced liquid biopsy technologies to enhance cancer care.
Read more →-DGX
Apr 16, 2026City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers
Quest Diagnostics announced that City of Hope will evaluate its Haystack MRD test in clinical trials for patients with breast, colorectal, ovarian, and prostate cancers. The multi-year program aims to improve patient management by detecting minimal residual disease and monitoring treatment responses. The collaboration is expected to provide significant insights into the effectiveness of ctDNA testing in oncology.
Read more →-DGX
Mar 12, 2026Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors SECAUCUS, N.J., March 12 , 2026 -- Quest Diagnostics Incorporated (
Quest Diagnostics has elected Timothy Wentworth, former CEO of Walgreens Boots Alliance and Evernorth Health Services, to its board of directors. This addition expands the board to eleven members, enhancing its leadership with Wentworth's extensive experience in the healthcare sector. His background includes significant roles at prominent organizations, which could benefit Quest as it aims to improve healthcare delivery. The company highlights Wentworth's operational and HR expertise as valuable assets in achieving its mission.
Read more →-DGX
Feb 26, 2026Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer
Quest Diagnostics has appointed Benjamin Beauvalot as Senior Vice President and Chief Strategy and M&A Officer. With over 20 years of experience in business strategy and transformation, Beauvalot will lead the company's growth strategy and M&A efforts. He succeeds Dermot Shorten, who is retiring after overseeing numerous business combinations during his tenure.
Read more →-DGX
Feb 26, 2026Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference
Quest Diagnostics announced that CFO Sam Samad will present at the Leerink 2026 Global Healthcare Conference. The presentation will cover the company's strategy, performance, and market trends. The event is scheduled for March 11, 2026, and will be available via live webcast and archived for later viewing.
Read more →-DGX
Feb 10, 2026▲ +7.4%on this news
Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization
Quest Diagnostics has announced a 7.5% increase in its quarterly cash dividend, raising it to $0.86 per share, effective April 20, 2026. This marks the 15th consecutive year of dividend increases. Additionally, the company has authorized a $1 billion increase in its share repurchase program, supplementing the existing $0.4 billion available as of December 31, 2025.
Read more →-DGX
Feb 10, 2026▲ +7.4%on this news
Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share
Quest Diagnostics reported strong financial results for Q4 and full year 2025, showcasing double-digit growth in revenues and earnings per share. The company also provided optimistic guidance for 2026 and announced a 7.5% increase in its quarterly dividend. CEO Jim Davis emphasized the company's commitment to clinical innovations and strategic collaborations.
Read more →-DGX
Feb 3, 2026Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease
Quest Diagnostics has launched a novel blood test, the Quest Flow Cytometry MRD for Myeloma, which utilizes advanced flow cytometry methods to detect measurable residual disease in myeloma patients. This test offers sensitivity comparable to next-generation sequencing at a lower cost and features five-day specimen stability. It aims to improve patient care and monitoring in clinical trials.
Read more →-DGX
Jan 12, 2026Driving Sustainable Growth, Delivering Long-term Value Jim Davis Chairman, CEO, and President J.P. Morgan Healthcare Conference
During the J.P. Morgan Healthcare Conference, Quest Diagnostics outlined its strategy for sustainable growth and long-term value. The company aims to innovate and provide actionable health insights while expanding its services across the U.S. and Canada. Quest anticipates significant growth in revenue and adjusted EPS, driven by advancements in lab diagnostics and strong consumer demand for health services. However, risks related to economic fluctuations and potential regulatory challenges remain.
Read more →-DGX
Jan 9, 2026Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026
Quest Diagnostics has announced the release date for its fourth quarter and full year 2025 financial results, set for February 10, 2026. The results will be discussed in a conference call at 8:30 a.m. ET on the same day. Participants can access the call via phone or online, with replays available afterward.
Read more →-DGX
Dec 22, 2025Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference
Quest Diagnostics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Jim Davis and CFO Sam Samad will discuss the company's strategy and market developments. The session will be webcast live and available for later viewing.
Read more →-DGX
Oct 21, 2025Quest Diagnostics Reports Third Quarter 2025 Financial Results Raises Guidance for Full Year 2025 Third quarter revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ( EPS ) of $
Quest Diagnostics announced its third quarter 2025 financial results, reporting revenues of $2.82 billion, a 13.1% increase compared to the previous year. The company raised its full year guidance for 2025, with expected diluted EPS between $8.58 and $8.66. Notable developments included a new joint venture with Corewell Health to create a lab services collaboration and acquisition of dialysis testing assets. The company also focuses on enhanced consumer health solutions and ongoing improvement in operational performance.
Read more →-DGX
Jul 22, 2025▲ +7.1%on this news
Quest Diagnostics Reports Second Quarter 2025 Financial Results Raises Guidance for Full Year 2025 Second quarter revenues of $2.76 billion, up 15.2% from 2024 Second quarter reported diluted earnings per share ( EPS ) o
Quest Diagnostics reported a significant increase in their second quarter 2025 financial results, with revenues reaching $2.76 billion, up 15.2% from the previous year. The diluted earnings per share increased by 21.7% year-over-year, showcasing strong operational performance. Due to continued demand and productivity gains driven by automation, the company has raised its full year guidance for 2025. Quest's results reflect effective strategy execution and growth from both organic sources and acquisitions.
Read more →-DGX
Apr 22, 2025▲ +6.8%on this news
Quest Diagnostics Reports First Quarter 2025 Financial Results Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025 First quarter revenues of $2.65 billion, up 12.1% from 2024 First quarter reported dil
Quest Diagnostics reported financial results for the first quarter of 2025, achieving revenues of $2.65 billion, which marks a 12.1% increase from the previous year. The diluted earnings per share (EPS) also showed significant growth, with reported EPS increasing by 12.8% and adjusted EPS by 8.3%. The company reaffirmed its overall guidance for the full year 2025, expecting revenues to be between $10.70 billion and $10.85 billion, with EPS projected in a similar range. This performance is attributed to strong demand and contributions from acquisitions, despite prior challenges earlier in the quarter.
Read more →-DGX
Mar 19, 2025INVESTOR DAY PRESENTATION (DAVIS) Investor Day 2025 Quest Diagnostics Driving Sustainable Growth, Delivering Long-term Value Jim Davis Chairman, CEO, and President Investor Day 2025 Quest Diagnostics Safe harbor disclosu
Quest Diagnostics held its Investor Day 2025 presentation, detailing its strategy for driving sustainable growth and delivering long-term value. The company highlighted the expected strong performance of the clinical lab market due to health trends and innovations in diagnostics. Quest aims to achieve significant revenue growth through key investments and improvements in operational strategies, targeting a 4%-5% CAGR in revenue and a 7%-9% CAGR in adjusted EPS beyond 2025.
Read more →-DGX
Mar 19, 2025Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day Provides long-term outlook beyond 2025: Revenues expected to grow
Quest Diagnostics outlined its strategic priorities during its 2025 Investor Day, focusing on sustainable growth and enhancing shareholder value. The company projected long-term revenue growth at a compound annual growth rate (CAGR) of 4-5%, coupled with an adjusted EPS growth of 7-9%. Strategic initiatives discussed included investments in automation, AI, and a significant IT modernization effort. Additionally, Quest reaffirmed its revenue guidance for 2025, despite anticipating a $25 million revenue impact due to adverse weather conditions.
Read more →-DGX
Jan 30, 2025▲ +5.6%on this news
Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results Provides Guidance for Full Year 2025 Increases Quarterly Dividend 6.7% to $0.80 Per Share Fourth quarter revenues of $2.62 billion, up 14.5% f
Quest Diagnostics reported a strong performance for the fourth quarter and full year of 2024, with revenues of $2.62 billion and $9.87 billion respectively. The quarterly and annual earnings per share also showed significant growth, bolstered by a series of successful acquisitions and an expanding advanced diagnostics portfolio. The company announced a 6.7% increase in its quarterly dividend and provided optimistic financial guidance for 2025, signaling confidence in its operational strength and growth prospects. Overall, the report reflects a positive trajectory for Quest Diagnostics moving into 2025.
Read more →-DGX
Oct 22, 2024▲ +6.9%on this news
Quest Diagnostics Reports Third Quarter 2024 Financial Results Updates Guidance for Full Year 2024 Third quarter revenues of $2.49 billion, up 8.5% from 2023 Third quarter reported diluted earnings per share ( EPS ) of $
Quest Diagnostics announced its financial results for the third quarter of 2024, reporting revenues of $2.49 billion, an increase of 8.5% from the prior year. The adjusted diluted earnings per share rose to $2.30, up 3.6% year-over-year. The company updated its full-year guidance, projecting total revenues between $9.80 billion and $9.85 billion, influenced by recent acquisitions, although it noted potential negative impacts from Hurricane Milton. Overall, the company expressed confidence in its growth trajectory moving into 2025.
Read more →-DGX
Aug 29, 2024dgx082320248-kex991
dgx082320248-kex991
Read more →-DGX
Aug 15, 2024Quest Diagnostics Prices $1.85 Billion of Senior Notes Secaucus, NJ
Quest Diagnostics has announced the pricing of $1.85 billion in senior notes, consisting of three tranches that will mature between 2027 and 2034. The proceeds are primarily aimed at financing the acquisition of LifeLabs, which the company has previously disclosed. Additionally, the structure of the notes includes provisions for mandatory redemption in case the acquisition does not go through. The offerings reflect strong market support for the company's strategic initiatives in the healthcare sector.
Read more →-DGX
Jul 23, 2024Quest Diagnostics Reports Second Quarter 2024 Financial Results Raises Guidance for Full Year 2024 Second quarter revenues of $2.40 billion, up 2.5% from 2023 Second quarter reported diluted earnings per share ( EPS ) of
Quest Diagnostics reported second quarter financial results for 2024, presenting revenues of $2.40 billion, a 2.5% increase from the previous year. The company has raised its full year revenue guidance, expecting revenues between $9.50 billion and $9.58 billion. Despite these positives, reported diluted EPS fell by 1.0% and net income declined by 2.4% compared to the same quarter in 2023. Acquisitions aimed at enhancing growth and efficiency were also highlighted, although cash flow from operations saw a notable decrease.
Read more →-DGX
Jul 3, 2024Quest Diagnostics to Acquire LifeLabs from OMERS, Enhancing Diagnostic Services for Canadians Secaucus, NJ and Toronto, Canada
Quest Diagnostics has announced an agreement to acquire LifeLabs for approximately CAN $1.35 billion, aiming to enhance diagnostic services for Canadians. The deal is expected to generate around CAN $970 million in annual revenue, aligning with Quest's growth strategy. LifeLabs will retain its brand and management, continuing to serve its Canadian customer base. The transaction is anticipated to close by the end of the year, subject to regulatory approvals. Quest's extensive experience and innovation are expected to strengthen LifeLabs' service delivery and operational capabilities.
Read more →-DGX
May 16, 2024Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors SECAUCUS, N.J.
Quest Diagnostics has elected Robert B. Carter, CIO of FedEx Corporation, to its Board of Directors. Mr. Carter brings over 30 years of technology and leadership experience from FedEx, where he has significantly influenced IT direction. His expertise in cloud technologies and cybersecurity is expected to be beneficial as Quest continues to enhance its services using advanced technologies. This addition expands Quest’s board to 10 members, reflecting a strong commitment to technological innovation in healthcare.
Read more →-DGX
Apr 23, 2024▲ +5.1%on this news
Quest Diagnostics Reports First Quarter 2024 Financial Results Raises Guidance for Full Year 2024 First quarter revenues of $2.37 billion, up 1.5% from 2023 First quarter reported diluted earnings per share ( EPS ) of $1
Quest Diagnostics reported its financial results for the first quarter of 2024, showing revenues of $2.37 billion, an increase of 1.5% compared to the same period in 2023. The company experienced nearly 6% base business revenue growth and raised its full-year revenue and earnings guidance due to strong market demand and strategic investments in diagnostics. The reported diluted earnings per share (EPS) decreased by 3.4%, indicating some challenges, but overall performance reflects positive momentum in their business operations.
Read more →-DGX
Feb 1, 2024Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results Provides Guidance for Full Year 2024 Increases Quarterly Dividend 5.6% to $0.75 Per Share Fourth quarter revenues of $2.29 billion, down 1.9%
Quest Diagnostics reported its financial results for Q4 and the full year 2023, highlighting a revenue drop of 1.9% in Q4 and a 6.4% decrease for the year overall. Nevertheless, the company saw a strong growth of 7.1% in base business revenues and a significant increase in diluted earnings per share. Looking ahead, Quest provided guidance expecting a slight revenue growth in FY 2024 and announced a dividend increase. However, COVID-19 testing revenues plummeted, marking a notable decline from the previous year.
Read more →-DGX
Nov 1, 2023government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, ch
Quest Diagnostics announced the pricing of $750 million in senior notes due 2033, expecting to close the offering on November 1, 2023. The proceeds will be used for general corporate purposes, including debt repayment of existing notes and borrowings. Despite the positive step of raising funds, the company pointed out potential risks such as government investigations and the complexities inherent in billing and revenue recognition.
Read more →-DGX
Oct 24, 2023Quest Diagnostics Reports Third Quarter 2023 Financial Results Updates Guidance for Full Year 2023 Third quarter revenues of $2.30 billion, down 7.7% from 2022 Third quarter reported diluted earnings per share ( EPS ) of
Quest Diagnostics reported a 7.7% decrease in total revenues for the third quarter of 2023, amounting to $2.30 billion. Despite this decline, the company experienced a 4.6% increase in base business revenues and emphasized successful negotiations of strategic health plan renewals. Updated full-year revenue guidance suggests a slight improvement, projecting revenues between $9.19 billion and $9.24 billion, with a continued emphasis on growth in professional lab services and M&A opportunities. However, the significant drop in COVID-19 testing revenues remains a concern.
Read more →-DGX
Jul 26, 2023▼ -6%on this news
Quest Diagnostics Reports Second Quarter 2023 Financial Results Updates Guidance for Full Year 2023 Second quarter revenues of $2.34 billion, down 4.7% from 2022 Second quarter reported diluted earnings per share ( EPS )
Quest Diagnostics reported its financial results for the second quarter of 2023, highlighting a revenue decrease of 4.7% year-over-year, totaling $2.34 billion. Despite the decline in total revenues, the company noted strong base business performance with a 9.5% revenue increase from health system customers. Adjusted diluted EPS showed a slight drop of 2.5%, and the company provided updated guidance for the full year, expecting revenues between $9.12 billion and $9.22 billion. The challenges of a tight labor market and declined COVID-19 testing revenue significantly impacted overall financial performance.
Read more →-DGX
Apr 27, 2023Quest Diagnostics Reports First Quarter 2023 Financial Results Updates Guidance for Full Year 2023 First quarter revenues of $2.33 billion, down 10.7% from 2022 First quarter reported diluted earnings per share ( EPS ) o
Quest Diagnostics reported its first quarter 2023 financial results, revealing a revenue decline of 10.7% year-over-year, totaling $2.33 billion. The company noted a significant drop in earnings, with reported diluted EPS down by 39.0%. Despite these challenges, base business revenues grew by 10.0%, reflecting strong performance across physician and hospital customers. The company also updated its full year 2023 guidance, anticipating revenues between $8.93 billion and $9.08 billion, amid ongoing declines in COVID-19 testing revenues.
Read more →-DGX
Mar 17, 2023Quest Diagnostics to Discuss Strategic Priorities to Drive Growth and Create Shareholder Value at 2023 Investor Day Updates 2023-26 compound annual growth rate (CAGR): Revenues expected to grow at mid singl
Quest Diagnostics held its Investor Day to discuss strategic priorities aimed at enhancing growth and shareholder value. The company provided an updated financial outlook for 2023-2026, predicting revenue growth at a mid single-digit CAGR and adjusted EPS growth at a high single-digit CAGR. CEO Jim Davis emphasized the importance of focusing on molecular genomics and consumer health to achieve these objectives. Additionally, the company will highlight operational productivity initiatives and capital deployment strategies during the event.
Read more →-DGX
Mar 7, 2023Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board SECAUCUS, N.J., DATE PRNewswire -- Quest Diagnostics (NYSE DGX), the world's leading provider of diagnostic information services, today ann
Quest Diagnostics has elected James E. Davis as Chairman of the Board, effective April 1, 2023. Davis, who is also the company's CEO and President, succeeds Steve Rusckowski in this added role. The board believes that merging the Chairman and CEO positions under Davis's leadership would best serve the shareholders and effectively execute the company’s strategy. Davis has been with Quest since 2013 and has held various executive roles, showcasing a steady leadership transition within the company.
Read more →-DGX
Feb 2, 2023QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS PROVIDES GUIDANCE FOR FULL YEAR 2023 Fourth quarter revenues of $2.33 billion, down 15.0% from 2021 Fourth quarter reported diluted earnings p
Quest Diagnostics reported financial results for the fourth quarter and full year of 2022, showing a decline in overall revenues and earnings compared to 2021. Fourth quarter revenues were $2.33 billion, down 15.0%, with diluted earnings per share decreasing by 72.1%. However, base business revenues grew 6.3% in Q4 and 5.1% for the full year, indicating stronger performance outside of COVID-19 testing. For 2023, the company aims to drive productivity and margin expansion despite the ongoing decline in COVID-19 testing revenues.
Read more →-DGX
Nov 1, 2022Quest Diagnostics Completes Leadership Succession as Jim Davis Becomes CEO and President, Joins Board of Directors - Former CEO Steve Rusckowski remains as Chairman through March 2023 Secaucus, NJ
Quest Diagnostics Completes Leadership Succession as Jim Davis Becomes CEO and President, Joins Board of Directors -Former CEO Steve Rusckowski remains as Chairman through March 2023 Secaucus, NJ, Nov. 1, 2022 - Quest Diagnostics (NYSE DGX), the world's leading provider of dia
Read more →-DGX
Oct 20, 2022▲ +6.3%on this news
Quest Diagnostics Reports Third Quarter 2022 Financial Results Raises Guidance for Full Year 2022 Third quarter revenues of $2.49 billion, down 10.4% from 2021 Third quarter reported diluted earnings per share ( EPS ) of
Quest Diagnostics Reports Third Quarter 2022 Financial Results Raises Guidance for Full Year 2022 Third quarter revenues of $2.49 billion, down 10.4% from 2021 Third quarter reported diluted earnings per share ( EPS ) of $2.17, down 46.0% from 2021 and adjusted diluted EPS of
Read more →-DGX
Jul 21, 2022Quest Diagnostics Reports Second Quarter 2022 Financial Results Raises Guidance for Full Year 2022 Second quarter revenues of $2.45 billion, down 3.8% from 2021 Second quarter reported diluted earnings per share ( EPS )
Quest Diagnostics Reports Second Quarter 2022 Financial Results Raises Guidance for Full Year 2022 Second quarter revenues of $2.45 billion, down 3.8% from 2021 Second quarter reported diluted earnings per share ( EPS ) of $1.96, down 60.5% from 2021 and adjusted diluted EPS o
Read more →-DGX
Jun 9, 2022Quest Diagnostics Names Sam Samad Executive Vice President and Chief Financial Officer SECAUCUS, N.J.
Quest Diagnostics Names Sam Samad Executive Vice President and Chief Financial Officer SECAUCUS, N.J., June 9, 2022 -- Quest Diagnostics (NYSE DGX), the world's leading provider of diagnostic information services, announced today that Sam Samad will become Executive Vice Preside
Read more →-DGX
Apr 21, 2022Quest Diagnostics Reports First Quarter 2022 Financial Results Raises Guidance for Full Year 2022 First quarter revenues of $2.61 billion, down 4.0% from 2021 First quarter reported diluted earnings per share ( EPS ) of
Quest Diagnostics Reports First Quarter 2022 Financial Results Raises Guidance for Full Year 2022 First quarter revenues of $2.61 billion, down 4.0% from 2021 First quarter reported diluted earnings per share ( EPS ) of $2.92, down 15.6% from 2021 and adjusted diluted EPS of $
Read more →-DGX
Feb 3, 2022Quest Diagnostics Announces Leadership Succession Plan - Chairman and CEO Steve Rusckowski to remain CEO through October 2022 and continue as Executive Chairman - James E. Davis, Executive Vice President, G
Announces Leadership Succession Plan Secaucus, NJ, Feb. 3, 2022 - Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that its Board of Directors, as part of its ongoing leadership succession planning, has appointed
Read more →-DGX
Feb 3, 2022QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS PROVIDES GUIDANCE FOR FULL YEAR 2022 INCREASES QUARTERLY DIVIDEND 6.5% TO $0.66 PER SHARE Full year revenues of $10.79 billion, up 14.3% from
QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS PROVIDES GUIDANCE FOR FULL YEAR 2022 INCREASES QUARTERLY DIVIDEND 6.5% TO $0.66 PER SHARE Full year revenues of $10.79 billion, up 14.3% from 2020 Full year diluted earnings per share ( EPS ) of $15.
Read more →-DGX
Jan 12, 2022▼ -6.8%on this news
Document QUEST DIAGNOSTICS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2021
QUEST DIAGNOSTICS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS SECAUCUS, N.J., Jan. 12, 2022 - Quest Diagnostics Incorporated (NYSE DGX), the world's leading provider of diagnostic information services, announced today preliminary financial results f
Read more →-DGX
Oct 21, 2021Document Quest Diagnostics Reports Third Quarter 2021 Financial Results, Raises Outlook for Full Year 2021 Third quarter revenues of $2.77 billion, down 0.4% from 2020 Third quarter reported diluted earnings per share (
Quest Diagnostics Reports Third Quarter 2021 Financial Results, Raises Outlook for Full Year 2021 Third quarter revenues of $2.77 billion, down 0.4% from 2020 Third quarter reported diluted earnings per share ( EPS ) of $4.02, down 2.8% from 2020 and adjusted diluted EPS of $3.
Read more →-DGX
Aug 17, 2021Document EX 99.1 Quest Diagnostics Elects Tracey C. Doi to Board of Directors SECAUCUS, N.J.
Quest Diagnostics Elects Tracey C. Doi to Board of Directors SECAUCUS, N.J., August 17, 2021 PRNewswire -- Quest Diagnostics (NYSE DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Ms. Tracey C. Doi to
Read more →-DGX
Jul 22, 2021Document Quest Diagnostics Reports Second Quarter 2021 Financial Results Establishes Full Year 2021 Outlook Second quarter revenues of $2.55 billion, up 39.5% from 2020 Second quarter reported diluted earnings per share
Quest Diagnostics Reports Second Quarter 2021 Financial Results Establishes Full Year 2021 Outlook Second quarter revenues of $2.55 billion, up 39.5% from 2020 Second quarter reported diluted earnings per share ( EPS ) of $4.96, up 264.2% from 2020 and adjusted diluted EPS of
Read more →-DGX
Apr 22, 2021Document Quest Diagnostics Reports First Quarter 2021 Financial Results Announces Plan for $1.5 Billion Accelerated Share Repurchase First quarter revenues of $2.72 billion, up 49.3% from 2020 First quarter reported dilu
Quest Diagnostics Reports First Quarter 2021 Financial Results Announces Plan for $1.5 Billion Accelerated Share Repurchase First quarter revenues of $2.72 billion, up 49.3% from 2020 First quarter reported diluted earnings per share ( EPS ) of $3.46, up 375.8% from 2020 and a
Read more →-DGX
Mar 11, 2021Quest Diagnostics Updates Strategic Growth Drivers and Provides Long-Term Outlook at 2021 Virtual Investor Day Company to repurchase $900 million of its shares in first half of 2021 Long-term outlook 2022-24 compound ann
Quest Diagnostics Updates Strategic and Provides Long-Term Outlook at 2021 Virtual Investor Day SECAUCUS, N.J., March 11, 2021 -- At a virtual meeting with analysts and investors at its Investor Day, members of the senior management team of Quest Diagnostics Incorporated (NYS
Read more →-DGX
Feb 23, 2021Quest Diagnostics Announces Board Leadership Changes --Daniel C. Stanzione to Retire from Board and as Lead Independent Director --Timothy M. Ring Selected New Lead Independent Director --Vicky B. Gregg Selected Chair, C
Quest Diagnostics Announces Board Leadership --Daniel C. Stanzione to Retire from Board and as Lead Independent Director --Timothy M. Ring Selected New Lead Independent --Vicky B. Gregg Selected Chair, Compensation Secaucus, N.J., Feb 23, 2021 /PR/Newswire/ -- Quest Diagnost
Read more →-DGX
Feb 4, 2021QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS ESTABLISHES OUTLOOK FOR FIRST HALF OF 2021 Fourth quarter revenues of $3.0 billion, up 55.8% versus 2019 Fourth quarter diluted earnings per s
QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS ESTABLISHES OUTLOOK FOR FIRST HALF OF 2021 Fourth quarter revenues of $3.0 billion, up 55.8% versus 2019 Fourth quarter diluted earnings per share from continuing operations ( EPS ) of $4.21, up 126.9
Read more →-DGX
Dec 16, 2020Document QUEST DIAGNOSTICS RAISES OUTLOOK FOR FULL YEAR 2020 Revenues for full year 2020 expected to be at least $9.35 billion versus the previous outlook of $8.8-$9.1 billion Reported diluted earnings per share (EPS) fo
QUEST DIAGNOSTICS RAISES OUTLOOK FOR FULL YEAR 2020 Revenues for full year 2020 expected to be at least $9.35 billion versus the previous outlook of $8.8-$9.1 billion Reported diluted earnings per share (EPS) for full year 2020 expected to be at least $9.98 versus the previous
Read more →-DGX
Oct 22, 2020Document Quest Diagnostics Reports Third Quarter 2020 Financial Results, Reflecting Continued Demand for COVID-19 Testing and Rapid Recovery in Health Care Utilization Third quarter revenues of $2.79 billion, up 42.5% fr
Quest Diagnostics Reports Third Quarter 2020 Financial Results, Reflecting Continued Demand for COVID-19 Testing and Rapid Recovery in Health Care Utilization Third quarter revenues of $2.79 billion, up 42.5% from 2019 Third quarter reported diluted earnings per share from cont
Read more →-DGX
Sep 10, 2020Document QUEST DIAGNOSTICS UPDATES OUTLOOK FOR FULL YEAR 2020 Revenues for full year 2020 now expected to be $8.4-8.8 billion compared to the previous outlook of $8.0-8.6 billion Reported diluted earnings per share (EPS)
QUEST DIAGNOSTICS UPDATES OUTLOOK FOR FULL YEAR 2020 Revenues for full year 2020 now expected to be $8.4-8.8 billion compared to the previous outlook of $8.0-8.6 billion Reported diluted earnings per share (EPS) for full year 2020 now expected to be $7.42-$8.92 compared to the
Read more →-DGX
Jul 23, 2020Document QUEST DIAGNOSTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Second quarter revenues of $1.83 billion, down 6.4% from 2019 Second quarter reported diluted earnings per share from continuing operations ( EPS )
QUEST DIAGNOSTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Second quarter revenues of $1.83 billion, down 6.4% from 2019 Second quarter reported diluted earnings per share from continuing operations ( EPS ) of $1.36, down 9.7% from 2019 and adjusted diluted EPS of $1.42, d
Read more →-DGX
May 11, 2020SECAUCUS, N.J.
11, 2020 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $550 million aggregate principal amount of its 2.800% senior notes due 2031 under Quest Diag
Read more →-DGX
May 4, 2020FOURTH AMENDED AND RESTATED RECEIVABLES SALES AGREEMENT Execution Version FOURTH AMENDED AND RESTATED RECEIVABLES SALE AGREEMENT dated as of
FOURTH AMENDED AND RESTATED RECEIVABLES dated as of October 28, 2015 QUEST DIAGNOSTICS INCORPORATED AND EACH OF ITS DIRECT OR INDIRECT SUBSIDIARIES WHO IS OR HEREAFTER BECOMES A SELLER HEREUNDER, QUEST DIAGNOSTICS RECEIVABLES INC., ARTICLE I. AMOUNTS AND TERMS OF THE PURCHAS
Read more →-DGX
Apr 22, 2020On March 31, 2020, Quest Diagnostics filed a Current Report on Form 8-K with the Securities and Exchange Commission to outline the impact of the COVID-19 pandemic on its operating
QUEST DIAGNOSTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS SECAUCUS, N.J., April 22, 2020 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the first quarter ended March 31, 20
Read more →-DGX
Apr 13, 2020LETTER TO QUEST COLLEAGUES An email to colleagues about our business from Steve Rusckowski Colleagues, The past few weeks have been a time of unprecedented challenges, and we have all seen the impact of the COVID-19 cris
colleagues about our business from Steve Rusckowski The past few weeks have been a time of unprecedented challenges, and we have all seen the impact of the COVID-19 crisis on our families, colleagues, communities, and our business. Thank you for the role you are playing in Que
Read more →-DGX
Mar 12, 2020Quest Diagnostics Elects Wright Lassiter III to Board of Directors
Quest Diagnostics Elects Wright Lassiter III to Board of Directors SECAUCUS, N.J., March 12, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Mr. Wright L.
Read more →-DGX
Dec 9, 2019Quest Diagnostics Prices $800 Million of Senior Notes
Quest Diagnostics Prices $800 Million of Senior Notes SECAUCUS, N.J., Dec. 9, 2019 -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $800 million aggregate princip
Read more →-DGX
Oct 22, 2019changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the company's most recently filed A
QUEST DIAGNOSTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS SECAUCUS, N.J., October 22, 2019 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the third quarter ended September
Read more →-DGX
Jul 23, 2019management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially differe
QUEST DIAGNOSTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS SECAUCUS, N.J., July 23, 2019 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the second quarter ended June 30, 20
Read more →-DGX
Feb 19, 2019Quest Diagnostics Elects Denise Morrison to Board of Directors SECAUCUS, N.J.
Quest Diagnostics Elects Denise Morrison to Board of Directors SECAUCUS, N.J., February 19, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Denise M. Morri
Read more →-DGX
Feb 14, 2019QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2019 Fourth quarter revenues of $1.84 billion , down 1.4% versus 2017 Fourth quarter diluted EPS of $0.92 on
QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2019 SECAUCUS, N.J., February 14, 2019 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today fi
Read more →-DGX
Nov 28, 2018Quest Diagnostics to Discuss Strategic Growth Drivers and Financial Outlook at 2018 Investor Day Provides outlook for 2019-2022, extending the company's targeted 3-5% revenue compound annual growth rate (CAGR) and updati
Quest Diagnostics to Discuss Strategic Growth Drivers and Financial Outlook at 2018 Investor Day SECAUCUS, N.J., Nov. 28, 2018 -- At a meeting with analysts and investors at its Investor Day tomorrow, members of the senior management team of Quest Diagnostics Incorporated (NYSE:
Read more →-DGX
Oct 23, 2018The statements in this press release which are not historical facts may be forward-looking statements.
QUEST DIAGNOSTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS SECAUCUS, N.J., October 23, 2018 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the third quarter ended September
Read more →-DGX
Jul 24, 2018actual results and outcomes to be materially different.
QUEST DIAGNOSTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS SECAUCUS, N.J., July 24, 2018 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the second quarter ended June 30, 20
Read more →-DGX
May 25, 2018UnitedHealthcare Establishes Long-term Strategic Partnership with Quest Diagnostics
UnitedHealthcare Establishes Long-term Strategic Partnership with Quest Diagnostics MINNEAPOLIS and SECAUCUS, N.J., (May 24, 2018) - UnitedHealthcare and Quest Diagnostics (NYSE: DGX) have established a long-term strategic partnership as the two organizations focus on ways to cr
Read more →-DGX
Feb 1, 2018QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2018; INCREASES DIVIDEND 11% TO $0.50 PER QUARTER Fourth quarter revenues of $1.94 billion , up 4.1% versus 2
QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2018; INCREASES DIVIDEND 11% TO $0.50 PER QUARTER SECAUCUS, N.J., February 1, 2018 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnos
Read more →-DGX
Nov 20, 2017Quest Diagnostics Provides Update on Impact of Final 2018 Medicare Payment Rates for Clinical Laboratory Tests SECAUCUS, N.J.
Quest Diagnostics Provides Update on Impact of Final 2018 Medicare Payment Rates for Clinical Laboratory Tests SECAUCUS, N.J., Nov. 20, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today provided an update o
Read more →-DGX
Sep 27, 2017Quest Diagnostics Provides Update On Impact to Third Quarter Financial Results from Hurricanes SECAUCUS, NJ
Quest Diagnostics Provides Update On Impact to Third Quarter Financial Results from Hurricanes SECAUCUS, NJ --Sept. 27, 2017-Quest Diagnostics Incorporated (NYSE:DGX), the world's leading provider of diagnostic information services, announced today that for the third quarter of
Read more →-DGX
Jul 25, 2017QUEST DIAGNOSTICS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS, RAISES 2017 FINANCIAL OUTLOOK Second quarter revenues of $1.94 billion , up 1.9% on a reported basis and up 2.3% on an equivalent basis versus 2016. Second
7/24/17 1:00 PM FINAL Exhibit 99.1 QUEST DIAGNOSTICS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS, RAISES 2017 FINANCIAL OUTLOOK MADISON, N.J., July 25, 2017 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announce
Read more →-DGX
Apr 20, 2017QUEST DIAGNOSTICS REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS, RAISES 2017 FINANCIAL OUTLOOK First quarter revenues of $1.90 billion , up 1.9% on a reported basis and up 3.0% on an equivalent basis versus 2016 First qua
QUEST DIAGNOSTICS REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS, RAISES 2017 FINANCIAL OUTLOOK MADISON, N.J., April 20, 2017 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the fi
Read more →-DGX
Jan 26, 2017QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2017 Fourth quarter revenues of $1.86 billion , up 0.7% on a reported basis and up 1.9% on an equivalent basi
QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2017 MADISON, N.J., JANUARY 26, 2017 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today fin
Read more →-DGX
Dec 15, 2016Quest Diagnostics Board of Directors Elects Stephen H. Rusckowski Chairman of the Board Daniel C. Stanzione Named Lead Independent Director Madison, N.J.
Quest Diagnostics Board of Directors Elects Stephen H. Rusckowski Chairman of the Board Daniel C. Stanzione Named Lead Independent Director Madison, N.J., December 15, 2016/PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information serv
Read more →-DGX
Nov 11, 2016Quest Diagnostics Raises Revenue Growth Outlook, Increases Dividend at 2016 Investor Day Revenue growth beyond 2016 to be between 3-5%, earnings to grow faster than revenues in mid-to-high single digit range Raises divid
Quest Diagnostics Raises Revenue Growth Outlook, Increases Dividend at 2016 Investor Day MADISON, NJ, November 11, 2016 - At a meeting with analysts and investors at its Investor Day today, members of the senior management team of Quest Diagnostics Incorporated (NYSE: DGX), the
Read more →-DGX
Sep 30, 2016QUEST DIAGNOSTICS REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS Revenues of $1.89 billion, up 0.3% on a reported basis and up 2.1% on an equivalent basis versus 2015 Reported diluted EPS of $1.34, down 43.0% from 2015 due
QUEST DIAGNOSTICS REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS MADISON, N.J., OCTOBER 20, 2016 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for the third quarter ended September 30, 2016, repo
Read more →-DGX
Jun 30, 2016QUEST DIAGNOSTICS REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS Q2 2016 revenues of $1.91 billion, lower by 1% on a reported basis and higher by 2.4% on an equivalent basis versus 2015 Reported diluted EPS of $1.37, up 6
QUEST DIAGNOSTICS REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS MADISON, N.J., JULY 21, 2016 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for the second quarter ended June 30, 2016, reported n
Read more →-DGX
May 23, 2016Quest Diagnostics Announces Proposed Senior Notes Offering
Quest Diagnostics Announces Proposed Senior Notes Offering MADISON, N.J., May 23, 2016 -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it intends to offer $500,000,000 aggregate principal amount
Read more →-DGX
May 18, 2016Quest Diagnostics Completes Effort to Refocus on Diagnostic Information Services; Updates 2016 Revenue Outlook - Strategy to refocus business portfolio completed with sale of Focus Diagnostics products business for $300
Quest Diagnostics Completes Effort to Refocus on Diagnostic Information Services; Updates 2016 Revenue Outlook - Strategy to refocus business portfolio completed with sale of Focus Diagnostics products business for $300 million - Full Year 2016 revenue now expected to be betwee
Read more →Competitive Position
How DGX ranks across every disease it competes inCompetitive Position is a premium feature
See how DGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial